Literature DB >> 27902996

Pemphigus: Pathogenesis to Treatment.

Christopher DiMarco1.   

Abstract

Pemphigus vulgaris (PV), pemphigus foliaceus (PF), and paraneoplastic pemphigus (PNP) are a group of rare and fatal blistering diseases involving autoantibodies that target desmosomal proteins. The pathogenesis of pemphigus involves the production of activated B-cells and IgG with stimulation by IL-4 by T-helper 2 cells. Clinically these diseases present most often with epidermal erosions of the mucosae and skin caused by rapid rupturing of flaccid bullae. These lesions correlate histologically with splits forming in the epidermis, leaving a blister roof composed of a few cell layers. Standard treatment of pemphigus involves oral corticosteroids, often with the addition of adjuvant therapies, to improve disease control, minimize corticosteroids side-effects, and increase the odds of remission. [Full article available at http://rimed.org/rimedicaljournal-2016-12.asp].

Entities:  

Keywords:  corticosteroids; desmoglein 1; desmoglein 3; paraneoplastic pemphigus; pemphigus foliaceus; pemphigus vulgaris

Mesh:

Substances:

Year:  2016        PMID: 27902996

Source DB:  PubMed          Journal:  R I Med J (2013)        ISSN: 0363-7913


  3 in total

Review 1.  Role of Regulatory Immune Cells and Molecules in Autoimmune Bullous Dermatoses.

Authors:  Tianyu Cao; Shuai Shao; Hui Fang; Bing Li; Gang Wang
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

2.  NEONATAL PEMPHIGUS IN AN INFANT BORN TO A MOTHER WITH PEMPHIGUS VULGARIS: A CASE REPORT.

Authors:  Adriana Amaral Carvalho; Dinamar Amador Dos Santos Neto; Mirelle Augusta Dos Reis Carvalho; Sabrina Jeane Prates Eleutério; Alessandra Rejane Ericsson de Oliveira Xavier
Journal:  Rev Paul Pediatr       Date:  2018-07-26

3.  Pemphigus vulgaris in an elderly woman diagnosed with subacute thyroiditis: A case report.

Authors:  Karla Maria Carvalho; Anita Dhupar; Anita Spadigam; Meghna Virendra Naik
Journal:  Aging Med (Milton)       Date:  2022-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.